Literature DB >> 27903713

'Trained immunity': consequences for lymphoid malignancies.

Wendy B C Stevens1, Mihai G Netea2,3, Arnon P Kater4, Walter J F M van der Velden5,3.   

Abstract

In hematological malignancies complex interactions exist between the immune system, microorganisms and malignant cells. On one hand, microorganisms can induce cancer, as illustrated by specific infection-induced lymphoproliferative diseases such as Helicobacter pylori-associated gastric mucosa-associated lymphoid tissue lymphoma. On the other hand, malignant cells create an immunosuppressive environment for their own benefit, but this also results in an increased risk of infections. Disrupted innate immunity contributes to the neoplastic transformation of blood cells by several mechanisms, including the uncontrolled clearance of microbial and autoantigens resulting in chronic immune stimulation and proliferation, chronic inflammation, and defective immune surveillance and anti-cancer immunity. Restoring dysfunction or enhancing responsiveness of the innate immune system might therefore represent a new angle for the prevention and treatment of hematological malignancies, in particular lymphoid malignancies and associated infections. Recently, it has been shown that cells of the innate immune system, such as monocytes/macrophages and natural killer cells, harbor features of immunological memory and display enhanced functionality long-term after stimulation with certain microorganisms and vaccines. These functional changes rely on epigenetic reprogramming and have been termed 'trained immunity'. In this review the concept of 'trained immunity' is discussed in the setting of lymphoid malignancies. Amelioration of infectious complications and hematological disease progression can be envisioned to result from the induction of trained immunity, but future studies are required to prove this exciting new hypothesis. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27903713      PMCID: PMC5479617          DOI: 10.3324/haematol.2016.149252

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  88 in total

1.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies.

Authors:  Anna Lanemo Myhrinder; Eva Hellqvist; Ekaterina Sidorova; Anita Söderberg; Helen Baxendale; Charlotte Dahle; Kerstin Willander; Gerard Tobin; Eva Bäckman; Ola Söderberg; Richard Rosenquist; Sohvi Hörkkö; Anders Rosén
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

Review 2.  Epigenetic control of myeloid cell differentiation, identity and function.

Authors:  Damiana Álvarez-Errico; Roser Vento-Tormo; Michael Sieweke; Esteban Ballestar
Journal:  Nat Rev Immunol       Date:  2015-01       Impact factor: 53.106

3.  PD-L1 blockade: rejuvenating T cells in CLL.

Authors:  Arnon P Kater; Gerritje J W van der Windt
Journal:  Blood       Date:  2015-07-09       Impact factor: 22.113

4.  Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial.

Authors:  Andrés J M Ferreri; Silvia Govi; Markus Raderer; Antonino Mulè; Alessandro Andriani; Daniele Caracciolo; Liliana Devizzi; Fiorella Ilariucci; Stefano Luminari; Edi Viale; Leonhard Müllauer; Stefania Dell'Oro; Paolo Giorgio Arcidiacono; Maurilio Ponzoni; Caterina Patti
Journal:  Blood       Date:  2012-11-01       Impact factor: 22.113

Review 5.  Immunomodulation and immune reconstitution in chronic lymphocytic leukemia.

Authors:  John C Riches; John G Gribben
Journal:  Semin Hematol       Date:  2014-05-15       Impact factor: 3.851

Review 6.  Impact of myeloid cells on the efficacy of anticancer chemotherapy.

Authors:  Laura Senovilla; Fernando Aranda; Lorenzo Galluzzi; Guido Kroemer
Journal:  Curr Opin Immunol       Date:  2014-06-18       Impact factor: 7.486

Review 7.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

8.  Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance.

Authors:  Teresa Jurado-Camino; Raúl Córdoba; Laura Esteban-Burgos; Enrique Hernández-Jiménez; Victor Toledano; Jose-Angel Hernandez-Rivas; Elena Ruiz-Sainz; Teresa Cobo; María Siliceo; Rebeca Perez de Diego; Cristobal Belda; Carolina Cubillos-Zapata; Eduardo López-Collazo
Journal:  J Immunol       Date:  2014-12-10       Impact factor: 5.422

Review 9.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.

Authors:  Catherine de Martel; Jacques Ferlay; Silvia Franceschi; Jérôme Vignat; Freddie Bray; David Forman; Martyn Plummer
Journal:  Lancet Oncol       Date:  2012-05-09       Impact factor: 41.316

10.  Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses.

Authors:  Silke Paust; Harvinder S Gill; Bao-Zhong Wang; Michael P Flynn; E Ashley Moseman; Balimkiz Senman; Marian Szczepanik; Amalio Telenti; Philip W Askenase; Richard W Compans; Ulrich H von Andrian
Journal:  Nat Immunol       Date:  2010-10-24       Impact factor: 25.606

View more
  9 in total

1.  Circadian rhythm influences induction of trained immunity by BCG vaccination.

Authors:  L Charlotte J de Bree; Vera P Mourits; Valerie Acm Koeken; Simone Jcfm Moorlag; Robine Janssen; Lukas Folkman; Daniele Barreca; Thomas Krausgruber; Victoria Fife-Gernedl; Boris Novakovic; Rob Jw Arts; Helga Dijkstra; Heidi Lemmers; Christoph Bock; Leo Ab Joosten; Reinout van Crevel; Christine S Benn; Mihai G Netea
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

2.  Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia.

Authors:  Gonzalo Blanco; Anna Puiggros; Barbara Sherry; Lara Nonell; Xavier Calvo; Eulàlia Puigdecanet; Pui Yan Chiu; Yasmine Kieso; Gerardo Ferrer; Florencia Palacios; Magdalena Arnal; María Rodríguez-Rivera; Eva Gimeno; Eugènia Abella; Kanti R Rai; Pau Abrisqueta; Francesc Bosch; Alexandre Calon; Ana Ferrer; Nicholas Chiorazzi; Blanca Espinet
Journal:  Exp Hematol       Date:  2021-01-07       Impact factor: 3.249

Review 3.  Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.

Authors:  Amy Hughes; Agnes S M Yong
Journal:  Front Immunol       Date:  2017-04-24       Impact factor: 7.561

Review 4.  Infectious Agents as Stimuli of Trained Innate Immunity.

Authors:  Paulina Rusek; Mateusz Wala; Magdalena Druszczyńska; Marek Fol
Journal:  Int J Mol Sci       Date:  2018-02-03       Impact factor: 5.923

5.  Ultrasound May Suppress Tumor Growth, Inhibit Inflammation, and Establish Tolerogenesis by Remodeling Innatome via Pathways of ROS, Immune Checkpoints, Cytokines, and Trained Immunity/Tolerance.

Authors:  Qian Yang; Ruijing Zhang; Peng Tang; Yu Sun; Candice Johnson; Jason Saredy; Susu Wu; Jiwei Wang; Yifan Lu; Fatma Saaoud; Ying Shao; Charles Drummer; Keman Xu; Daohai Yu; Rongshan Li; Shuping Ge; Xiaohua Jiang; Hong Wang; Xiaofeng Yang
Journal:  J Immunol Res       Date:  2021-02-09       Impact factor: 4.818

6.  Trained Immunity-Based Vaccine in B Cell Hematological Malignancies With Recurrent Infections: A New Therapeutic Approach.

Authors:  Juliana Ochoa-Grullón; Celina Benavente Cuesta; Ataúlfo González Fernández; Gustavo Cordero Torres; Cristina Pérez López; Ascensión Peña Cortijo; Laura Conejero Hall; Marta Mateo Morales; Antonia Rodríguez de la Peña; Carmen M Díez-Rivero; Edgard Rodríguez de Frías; Kissy Guevara-Hoyer; Miguel Fernández-Arquero; Silvia Sánchez-Ramón
Journal:  Front Immunol       Date:  2021-02-12       Impact factor: 7.561

7.  Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.

Authors:  Alba Rodríguez-García; María Linares; María Luz Morales; Sophie Allain-Maillet; Nicolas Mennesson; Ricardo Sanchez; Rafael Alonso; Alejandra Leivas; Alfredo Pérez-Rivilla; Edith Bigot-Corbel; Sylvie Hermouet; Joaquín Martínez-López
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

8.  Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab.

Authors:  Gianpaolo Marcacci; Giuseppe Fiorentino; Francesco Volzone; Umberto Falcone; Roberto Parrella; Daniela Donnarumma; Silvia D'Ovidio; Anna Annunziata; Giovanni Micallo; Giuseppe Portella; Annarosaria De Chiara; Rosaria De Filippi; Stefania Crisci; Antonio Pinto
Journal:  Infect Agent Cancer       Date:  2021-06-02       Impact factor: 2.965

Review 9.  Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy.

Authors:  Salvatrice Mancuso; Marta Mattana; Melania Carlisi; Marco Santoro; Sergio Siragusa
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.